

AGENDA

For a Regular Meeting of the

Santa Clara County Health Authority Pharmacy and Therapeutics Committee

Thursday, June 20, 2019, 6:00-8:00 PM

Santa Clara Family Health Plan, Redwood Conference Room

6201 San Ignacio Blvd., San Jose, CA 95119

1. Roll Call / Establish Quorum	Dr. Lin	6:00	5 min.
2. Public Comment Members of the public may speak to any item not on the agenda; two minutes per speaker. The Committee reserves the right to limit the duration of public comment period to 30 minutes	Dr. Lin	6:05	5 min.
3. Open Meeting Minutes Review SCFHP 1Q2019 P&T Open minutes Possible Action: Approve SCFHP P&T Open minutes	Dr. Lin	6:10	2 min.
4. Standing Agenda Items			
a. CMO Health Plan Updates	Dr. Nakahira	6:12	3 min.
b. SCFHP/DHCS Global DUR	Dr. Otomo	6:15	5 min.
i. Anticholinergic Initiative			
c. Appeals & Grievance	Mr. Breakbill	6:20	2 min.
i. 2018 4 th Quarter Report			
ii. 2019 1 st Quarter Report			
d. Emergency Supply Report	Dr. Nguyen	6:22	5 min.
i. 2018 2 nd Quarter Report			
ii. 2018 3 rd Quarter Report			
Adjourn to Closed Session <i>Pursuant to Welfare and Institutions Code Section 14087.36 (w)</i>			
5. Closed Meeting Minutes Review SCFHP 1Q2019 P&T Closed minutes Possible Action: Approve SCFHP P&T Closed minutes	Dr. Lin	6:27	2 min.
6. Metrics & Financial Updates			
a. Membership Report	Dr. Nakahira	6:29	2 min.
b. Pharmacy Dashboard	Dr. Otomo	6:31	3 min.
c. Drug Use Evaluation	Dr. McCarty	6:34	2 min.
d. Drug Utilization & Spend	Dr. McCarty	6:36	10 min.

7. **Discussion and Recommendations for Changes to SCFHP Cal MediConnect (CMC) Formulary & Coverage Determination Criteria**

- | | | | |
|--|-------------|------|--------|
| a. MedImpact 1Q2019 P&T Meetings Minutes | Dr. McCarty | 6:46 | 2 min. |
| b. MedImpact 2Q2019 P&T Part D Actions | | 6:48 | 2 min. |
- Possible Action:** Approve MedImpact Minutes & Actions

8. **Discussion and Recommendations for Changes to SCFHP Medi-Cal & Healthy Kids Formulary & Prior Authorization (PA) Criteria**

- | | | | |
|---|-------------|------|---------|
| a. Formulary Modifications | Dr. Otomo | 6:50 | 5 min. |
| Possible Action: Approve recommendations | | | |
| b. Fee-for-Service Contract Drug List Comparability | Dr. McCarty | 6:55 | 5 min. |
| Possible Action: Approve recommendations | | | |
| c. Prior Authorization Criteria | Dr. Nguyen | 7:00 | 10 min. |

- i. New or Revised Criteria
 1. Copaxone (glatiramer acetate)
 2. Diabetic supplies
 3. Non-Formulary
 4. Oncology
 5. Malarone (atovaquone-proguanil)
 6. Lysteda (tranexamic acid)
 7. Sporanox (itraconazole)
 8. Intron A (interferon alfa-2b)
 9. Gilenya (fingolimod)
 10. Avonex, Rebif (interferon beta-1a)
 11. Rhopressa (netarsudil)
 12. Santyl (collagenase)
 13. Ciprodex (ciprofloxacin-dexamethasone)
 14. Mycobutin (rifabutin)
 15. Norditropin Flexpro (somatropin)
 16. Makena (hydroxyprogesterone caproate)
- ii. Annual Review
 1. Tymlos (abaloparatide)
 2. Dovonex (calcipotriene)
 3. Restasis (cyclosporine)
 4. Enablex (darifenacin)
 5. Marinol (dronabinol)
 6. Hycet (hydrocodone-acetaminophen)
 7. Lupron/Lupron Depot (leuprolide)
 8. Provigil (modafinil)
 9. Lovaza (omega-3 acid ethyl esters)
 10. Nebupent (pentamidine)
 11. Elmiron (pentosan polysulfate sodium)
 12. Symlin (pramlintide)
 13. Lyrica (pregabalin)
 14. Exelon (rivastigmine)
 15. Revatio (sildenafil)
 16. Androgel (testosterone)
 17. Xenazine (tetrabenazine)
 18. Viroptic (trifluridine)
 19. Oral liquids – NF
 20. Pain medications – terminally ill

21. Reauthorization

Possible Action: Approve criteria

- | | | |
|---|--------------------------|----------------|
| <p>9. New Drugs and Class Reviews</p> <ul style="list-style-type: none"> a. Inhaled Glucocorticoids – Asthma/COPD b. Xelpros (latanoprost) – Prostaglandin analog c. Motegrity (prucalopride) – Chronic idiopathic constipation d. Dupixent (dupilumab) – Expanded indication e. Apadaz (benzhydrocodone/acetaminophen) – New Prodrug f. Spravato (esketamine) – Treatment Resistant Depression g. Spinal Muscular Atrophy - Zolgensma <i>*informational only</i> h. Hereditary & Acquired TTR-Mediated Amyloidosis - Tafamidis <i>*informational only</i> i. New Entities <i>*informational only</i> <ul style="list-style-type: none"> i. Edsivo (celiprolol) ii. NKTR-181 (loxicodegol) iii. Inbrija (levodopa) iv. Cablivi (caplacizumab-YHDP) v. Dovato (dolutegravir/lamivudine) vi. Diacomit (stiripentol) j. Oncology Update <i>*informational only</i> <ul style="list-style-type: none"> i. Elzonris (tagraxofusp-erzs) ii. Balversa (erdafitinib) iii. Herceptin Hylecta (trastuzumab/hyaluronidase) iv. Asparlas (calaspargase pefol-mknl) | <p>Dr. McCarthy 7:10</p> | <p>45 min.</p> |
|---|--------------------------|----------------|
- Possible Action:** Approve recommendations

Reconvene in Open Session

- | | | |
|---|-------------------------|---------------|
| <p>10. Discussion Items
New and Generic Pipeline</p> | <p>Dr. McCarty 7:55</p> | <p>5 min.</p> |
| <p>11. Adjournment
Next meeting Thursday, September 19, 2019</p> | <p>Dr. Lin 8:00</p> | |

Notice to the Public—Meeting Procedures

- Persons wishing to address the Committee on any item on the agenda are requested to advise the Recorder so that the Chairperson can call on them when the item comes up for discussion.
- In compliance with the Americans with Disabilities Act, those requiring accommodations in this meeting should notify Nancy Aguirre 48 hours prior to the meeting at 408-874-1835.
- To obtain a copy of any supporting document that is available, contact Nancy Aguirre at 408-874-1835. Agenda materials distributed less than 72 hours before a meeting can be inspected at the Santa Clara Family Health Plan offices at 6201 San Ignacio Avenue, San Jose.
- This agenda and meeting documents are available at www.scfhp.com